A carregar...
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regim...
Na minha lista:
| Publicado no: | World J Gastrointest Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6304303/ https://ncbi.nlm.nih.gov/pubmed/30595807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.528 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|